Medigene (MDG1) - TCR clinical trial initiation imminent

Edison Investment Research - Pharmaceutical & healthcare - Medigene: Medigene’s Q3 results are in line with our forecasts. The company has submitted its Phase I/II clinical trial application for its lead TCR cellular immunotherapy product candidate MDG1011 and anticipates initiation of the trial by year end. In addition to the upcoming trial initiation, Medigene has made numerous scientific and technological achievements in 2017, including presentations on its automated TCR identification platform and preclinical data on MDG1011. Partners have presented compassionate use data on DC vaccines in AML. We value Medigene at €316m (€14.3/share).
ISIN: DE000A1X3W00

Original Article: Medigene (MDG1) - TCR clinical trial initiation imminent

More From BioPortfolio on "Medigene (MDG1) - TCR clinical trial initiation imminent"

• Related Companies
• Related Events
• Related Clinical Trials
• Related PubMed Entries
• Related Medications